Název v českém jazyce neuveden, volný překlad: Účinnost a bezpečnost léčby chronické hepatitidy C u hemofiliků

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F05%3A00012511" target="_blank" >RIV/00843989:_____/05:00012511 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Efficacy and safety of chronic hepatitis C treatment in hemophilic patients

Popis výsledku v původním jazyce

BACKGROUND/AIMS: Chronic hepatitis C infection is very common among hemophiliacs in the developed World. METHODOLOGY: Retrospective evaluation of the treatment results in hemophiliacs with chronic hepatitis C, all infected with genotype 1b. Twelve patients were treated with interferon-alpha monotherapy, 21 patients with interferon-alpha and ribavirin, and 3 patients with pegylated interferon and ribavirin, all for 48 weeks. RESULTS: Sustained virologic response was not achieved in any of 12 patients treated with interferon-alpha alone. Combination therapy with interferon-alpha and ribavirin was associated with better results: 8/21 (38%) patients achieved sustained virologic responses. Combination therapy with pegylated interferon and ribavirin has beenused in 3 patients; sustained response was achieved in 2 patients. CONCLUSIONS: The efficacy of antiviral treatment in hemophiliacs did not differ from other patients with chronic hepatitis C.

Název v anglickém jazyce

Efficacy and safety of chronic hepatitis C treatment in hemophilic patients

Popis výsledku anglicky

BACKGROUND/AIMS: Chronic hepatitis C infection is very common among hemophiliacs in the developed World. METHODOLOGY: Retrospective evaluation of the treatment results in hemophiliacs with chronic hepatitis C, all infected with genotype 1b. Twelve patients were treated with interferon-alpha monotherapy, 21 patients with interferon-alpha and ribavirin, and 3 patients with pegylated interferon and ribavirin, all for 48 weeks. RESULTS: Sustained virologic response was not achieved in any of 12 patients treated with interferon-alpha alone. Combination therapy with interferon-alpha and ribavirin was associated with better results: 8/21 (38%) patients achieved sustained virologic responses. Combination therapy with pegylated interferon and ribavirin has beenused in 3 patients; sustained response was achieved in 2 patients. CONCLUSIONS: The efficacy of antiviral treatment in hemophiliacs did not differ from other patients with chronic hepatitis C.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FN - Epidemiologie, infekční nemoci a klinická imunologie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2005

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Hepato-Gastroenterology

ISSN

0172-6390

e-ISSN

—

Svazek periodika

Vol.52

Číslo periodika v rámci svazku

No.65

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

4

Strana od-do

—

Kód UT WoS článku

000232127700051

EID výsledku v databázi Scopus

—